**
In a striking revelation, internal records have uncovered a meeting between senior officials at the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This encounter, held on 17 June 2025, occurred amidst ongoing litigation against Bayer over its glyphosate-based herbicides, including the widely used Roundup. The discussions reportedly centred on the company’s attempts to mitigate legal challenges related to cancer claims linked to its products, raising alarming questions about the integrity of regulatory processes in the United States.
Corporate Interests vs. Public Health
The meeting took place as Bayer faced countless lawsuits from individuals asserting that their use of glyphosate herbicides had resulted in cancer diagnoses. Critics have long accused Bayer of neglecting to adequately inform consumers about potential health risks associated with their products. The core of Bayer’s defence rests on a contentious legal argument: if the EPA does not mandate a cancer warning for glyphosate, the company believes it cannot be held liable for failing to provide such warnings.
As the Trump administration took steps to bolster Bayer’s legal position, the implications of this meeting have raised serious concerns. An internal email from the EPA, dated 13 June, indicated that Bayer’s team intended to discuss “legal/judicial issues” including “supreme court action” during their time with EPA officials. This was less than two weeks before the Supreme Court requested input from the Trump administration’s Justice Department on whether to hear Bayer’s case.
A Pattern of Support for Bayer
The Trump administration’s actions following this meeting appear to reflect a systematic prioritisation of corporate interests over public health. In December 2025, D John Sauer, the solicitor general appointed by the Trump administration, urged the Supreme Court to take up Bayer’s case, a request the court subsequently granted, scheduling a hearing for 27 April. Furthermore, the White House invoked the Defense Production Act to ensure the continued production of glyphosate herbicides, effectively providing a form of “immunity” for manufacturers like Bayer.
In March 2026, Sauer submitted an amicus brief to the Supreme Court that explicitly backed Bayer’s legal arguments, a move that further highlights the administration’s alignment with corporate interests. Bayer has characterised the meeting as a routine part of the regulatory process, asserting that they have maintained transparency regarding their legal challenges. However, critics argue that such interactions reveal an unsettling imbalance in how regulatory bodies engage with corporate entities compared to the general public.
Voices of Concern
Environmental advocates have reacted strongly to the revelations regarding the EPA meeting. Nathan Donley, director of environmental health science at the Center for Biological Diversity, expressed profound concern over the apparent prioritisation of corporate profit over public health. “The political appointees at the EPA seem more invested in safeguarding pesticide company profits than ensuring the well-being of American citizens,” he stated.
Legal experts have echoed these sentiments, questioning the appropriateness of corporate executives meeting with high-ranking regulatory officials to discuss liability issues. Whitney Di Bona, a consumer safety advocate, remarked, “It’s alarming that the CEO of a major pesticide company can engage in private discussions with the EPA regarding limiting the company’s liability,” highlighting the stark contrast in access to regulatory dialogue for affected individuals versus corporate leaders.
Zen Honeycutt, founder of Moms Across America, noted that such instances of corporate coercion are not surprising. “Chemical companies have long exerted influence over our regulatory agencies,” she said, adding that despite numerous engagements with the EPA, advocacy groups have seen little action on calls to restrict or ban harmful pesticides.
Why it Matters
The meeting between Bayer executives and EPA officials underscores a troubling trend of corporate influence over environmental policy in the United States. As the battle over glyphosate continues to unfold, the implications for public health and safety cannot be overstated. With the stakes so high, it is imperative that regulatory bodies prioritise the voices of affected individuals and communities over corporate interests. The outcomes of these legal battles will not only determine Bayer’s future but also set a precedent for how environmental safety is governed in the country, making it a critical moment for public health advocates and concerned citizens alike.
